Although these pathophysiological connections are not well established, results from several observational studies and a few interventional trials support a beneficial effect of SGLT-2 inhibitors on AF incidence, burden, or outcomes in subjects with heart disease and diabetes [3]. Here, SLC5A2 is linked to atrial fibrillation.